Clovis Oncology, Inc.

DB:C6O Voorraadrapport

Marktkapitalisatie: €2.2m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Clovis Oncology Balans Gezondheid

Financiële gezondheid criteriumcontroles 0/6

Clovis Oncology has a total shareholder equity of $-417.9M and total debt of $660.4M, which brings its debt-to-equity ratio to -158%. Its total assets and total liabilities are $346.8M and $764.7M respectively.

Belangrijke informatie

-158.0%

Verhouding schuld/eigen vermogen

US$660.38m

Schuld

Rente dekkingsration/a
ContantUS$58.32m
Aandelen-US$417.89m
Totaal verplichtingenUS$764.66m
Totaal activaUS$346.78m

Recente financiële gezondheidsupdates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: C6O has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Langlopende schulden: C6O has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: C6O has negative shareholder equity, which is a more serious situation than a high debt level.

Schuld verminderen: C6O's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: Insufficient data to determine if C6O has enough cash runway based on its current free cash flow.

Voorspelling contante baan: Insufficient data to determine if C6O has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Ontdek gezonde bedrijven